Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase involved in signalling in many of the cells that drive immune inflammation. The development of small molecules that inhibit Syk kinase may change the way we treat disorders such as rheumatoid arthritis (RA), as well as a range of other inflammatory diseases. Fostamatinib (R-788) is an orally bioavailable small molecule. It is the prodrug of R406, which is a potent Syk inhibitor. Fostamatinib was developed because it has more favourable physiochemical properties. It is rapidly converted to R406 by intestinal enterocytes. It has been evaluated in experimental models of RA, such as collagen-induced arthritis. In these models, fostamatinib suppressed clinical arthritis, bone erosions, pannus formation and synovitis. A phase II programme with fostamatinib has largely been completed. Three key trials have been published, lasting 12-26 weeks and each enrolling 189-457 patients (875 in total). All these trials involved placebo therapy and patients continued to receive methotrexate in addition to active treatment with fostamatinib. The first dose-ranging trial evaluated three treatment doses in RA patients who had not fully responded to methotrexate therapy. The second trial compared two treatment doses in patients who had not responded to methotrexate therapy. The third trial compared a single treatment dose with placebo in patients who had not responded to biological therapy. The primary outcome measure was the number of patients achieving American College of Rheumatology (ACR) 20% (ACR20) responses. Placebo ACR20 response rates in all three trials were similar (35-38%). All three trials involved one treatment arm receiving fostamatinib 100 mg twice daily; ACR20 responses with this active treatment ranged from 38% to 67%. A meta-analysis of ACR responses in these trials, using responses to the highest dose in each trial for comparisons with placebo therapy in a random effects model, showed a borderline benefit with ACR20 responses. There were more significant differences with ACR50 and ACR70 responses. The reason that this meta-analysis was not more strongly positive is that the third trial, which evaluated patients who had failed to respond to biological treatments, gave negative results. Individual ACR response components, such as changes in swollen joint counts, showed significant differences in the first two trials, but there were no definite treatment benefits in the third trial. Overall, the differences were significant in a meta-analysis of all three trials. The most important adverse reactions were diarrhoea, neutropenia and raised ALT levels, which all showed significant excesses with active treatment compared with placebo. Too few patients have been studied for a definitive safety profile to be known. Overall, the results of the phase II trials were sufficiently encouraging for a phase III programme to be initiated. It will be some years before their definitive results are available.
Which enzyme is inhibited by a drug fostamatinib?

The people, later to be known as Frisii, began settling in Frisia in the 6th century BC. According to Pliny the Elder, in Roman times, the Frisians (or rather their close neighbours, the Chauci) lived on terps, man-made hills.
The Frisia was named for whom?

What could make Michael Jordon, one of the greatest basketball players in history, shed tears? It was when he became a member of the Basketball Hall of Fame on September 11. The hall is in Springfield, Massachusetts and honors the best basketball players, greatest coaches and other contributors to the game. "The game of basketball has been everything to me ," said Jordan, 46. "It is the place I have always gone when I needed to find comfort and peace." Jordan retired twice in his 15-year career, finishing with 32292 points, the third highest total points in NBA history behind Kareem Abdul-Jabbar and Karl Malone. His average of 30.12 points a game is the best in the League. "One day you might look up and see me playing the game at 50," Jordan said. "Because limits, like fears, are often just an illusion." In other words, it was motivation that made Jordan such a success.. A great career did not mean a smooth one. His high school coach cut him from the team in favor of a taller player when Jordan was in 10thgrade. His college coach wouldn't allow him on the cover of Sports Illustration in 1981 with North Carolina's four other players because Jordan was a freshman. In his first NBA All-Star game, older NBA stars wouldn't throw him the ball because of jealousy. "That burned me up," Jordan said. "But _ don't have to stop you. If you run into a wall, don't turn around and give up. Figure out how to climb it, go through it, or work around it."

Who scored the highest total points in NBA history?